How does the recombinant rabbit monoclonal antibody PDGFR/APDGFRB advance fibrosis disease research?

1. What is the core role of the PDGF/PDGFR signaling pathway in fibrotic diseases?

Fibrotic diseases are pathological processes characterized by persistent tissue damage leading to excessive activation of fibroblasts, deposition of extracellular matrix (ECM) that replaces functional tissue, and ultimately organ structural destruction and functional failure. This process affects multiple organs such as the heart, liver, lungs, kidneys, and skin, and is a major cause of disability and mortality in various chronic diseases. Within the complex signaling network driving fibrosis, the platelet-derived growth factor (PDGF) and its receptor (PDGFR) signaling pathway are recognized as a key driving axis. PDGF family members (primarily PDGF-A, -B, -C, -D) act as potent mitogenic and chemotactic factors, released by various cells (e.g., platelets, macrophages, endothelial cells, epithelial cells) after tissue injury. These ligands bind to specific tyrosine kinase receptors PDGFRα and PDGFRβ on target cells (mainly fibroblasts and their activated state—myofibroblasts), inducing receptor dimerization (forming αα, αβ, ββ dimers) and autophosphorylation, thereby activating downstream signaling pathways including PI3K-AKT, Ras-MAPK, STAT, PLCγ, among others. This cascade strongly promotes fibroblast proliferation, migration, survival, and stimulates the secretion of large amounts of collagen and other ECM components, directly driving the initiation and progression of fibrosis in multiple organs. Therefore, targeting the PDGF/PDGFR pathway is considered a highly promising strategy to halt or even reverse fibrosis.

2. Why is precise targeting of PDGFRα and PDGFRβ critical in anti-fibrotic therapy?

PDGFR exists in two subtypes: PDGFRα and PDGFRβ. They share overlapping yet distinct roles in tissue distribution, ligand-binding preferences, and physiological/pathological functions. Studies show that in different organ fibrosis models, the two receptors may play different roles. For example, in liver and pulmonary fibrosis, PDGFRβ activation is often emphasized as closely related to myofibroblast activation and proliferation, while in certain skin fibrosis or systemic sclerosis models, PDGFRα signaling also plays a significant role. Additionally, the binding of PDGF ligands to different receptor dimers activates partially divergent downstream effects. Therefore, an ideal therapeutic strategy requires precise analysis and intervention for both receptors. Pan-PDGFR inhibitors may provide comprehensive blockade but could also increase the risk of side effects by simultaneously affecting their physiological functions (e.g., angiogenesis, tissue repair). Selective targeting of PDGFRα or PDGFRβ may enable more precise intervention, addressing the fibrosis-driving mechanisms in specific organs or disease stages, and potentially improving the therapeutic window. This highlights the extreme importance of research tools capable of specifically identifying and distinguishing PDGFRα and PDGFRβ protein expression, activation states, and spatial distribution.

3. What unique advantages do PDGFRA/PDGFRB recombinant rabbit monoclonal antibodies offer in fibrosis research?

In exploring the specific mechanisms of PDGFRα/β in fibrosis and evaluating targeted therapies in preclinical studies, high-quality, highly specific antibodies are indispensable core tools. Compared to traditional polyclonal or mouse monoclonal antibodies, recombinant rabbit monoclonal antibodies targeting PDGFRα and PDGFRB exhibit significant advantages in multiple aspects:

1. Exceptional specificity and consistency: Recombinant rabbit monoclonal antibodies are produced based on a single recombinant gene sequence, recognizing a single, defined epitope. This ensures high batch-to-batch consistency and greatly reduces the risk of cross-reactivity due to recognition of multiple epitopes, enabling more reliable differentiation between the highly homologous PDGFRα and PDGFRβ proteins.

2. High affinity: Rabbit-derived antibodies typically have a richer antibody repertoire, enabling the generation of higher-affinity antibodies against certain mammalian proteins (e.g., human PDGFR), thereby providing stronger signals and lower background in detection, especially for low-expression tissue samples or post-translational modifications like phosphorylation.

3. Broad application compatibility: High-quality recombinant rabbit monoclonal antibodies are thoroughly validated for use in multiple key research platforms, including: immunohistochemistry/immunofluorescence (for precise localization and quantification of receptor expression and spatial distribution in different cell types, such as myofibroblasts and endothelial cells, in situ tissue sections); Western blotting (for detecting changes in total and phosphorylated receptor (p-PDGFR) protein levels in tissue or cell lysates); flow cytometry (for analyzing receptor expression abundance on specific cell populations); immunoprecipitation (for studying receptor-interacting proteins or downstream signaling complexes).

4. Support for in-depth mechanistic studies: Using these specific antibodies, researchers can deeply investigate: the expression dynamics, activation levels (phosphorylation), and their correlation with disease progression of PDGFRα and PDGFRβ in specific fibrosis models; differences in receptor expression on fibroblasts of different cellular origins; and the specific downregulation or signaling inhibition of receptors after targeted drug treatment.

4. Which manufacturers provide PDGFRA+PDGFRB recombinant rabbit monoclonal antibodies?

Hangzhou Start Biotech Co., Ltd. has independently developed the "PDGFRA+PDGFRB Recombinant Rabbit Monoclonal Antibody (PDGFRA+PDGFRB Recombinant Rabbit mAb (S-393-11))" (Catalog No.: S0B0541), a high-specificity, high-affinity, and highly stable dual-target antibody for detecting platelet-derived growth factor receptors. This product is developed using the S-RMab® recombinant rabbit monoclonal antibody platform technology and can simultaneously and specifically recognize human PDGFRA and PDGFRB receptor proteins. It performs excellently in applications such as Western blotting (WB), immunohistochemistry (IHC), and immunofluorescence (IF), making it a key tool for studying the PDGF signaling pathway, tumor angiogenesis, stromal cell function, and related disease mechanisms.

Core product advantages:

Professional technical support: We provide detailed validation data packages for this antibody, including dual-target specificity validation (for PDGFRA and PDGFRB), application data in various tumor or normal tissues, and recommended multi-platform experimental protocols. Our technical team offers professional consultation on signaling pathway research applications.

Hangzhou Start Biotech Co., Ltd. is committed to providing high-performance, high-value innovative antibody tools for tumor research, developmental biology, and fibrotic diseases. For more information about the "PDGFRA+PDGFRB Recombinant Rabbit Monoclonal Antibody" (Catalog No. S0B0541), to obtain validation data, or to request sample testing, please feel free to contact us.

Product Information

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.